Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.

Banerjee K, Michael E, Eggink D, van Montfort T, Lasnik AB, Palmer KE, Sanders RW, Moore JP, Klasse PJ.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):206-14. doi: 10.1089/aid.2011.0101. Epub 2011 Jul 27.

2.

Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

Banerjee K, Andjelic S, Klasse PJ, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP.

Virology. 2009 Jun 20;389(1-2):108-21. doi: 10.1016/j.virol.2009.04.001. Epub 2009 May 2.

3.

Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin.

Huang X, Jin W, Griffin GE, Shattock RJ, Hu Q.

J Gen Virol. 2011 Oct;92(Pt 10):2367-73. doi: 10.1099/vir.0.033092-0. Epub 2011 Jun 29.

PMID:
21715597
4.

Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site.

Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, Chakauya E, O'Keefe BR, Chikwamba R, Morris L.

J Virol. 2011 Sep;85(17):9039-50. doi: 10.1128/JVI.02675-10. Epub 2011 Jun 22.

5.

Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin.

Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, Mlisana K, Karim SS, McMahon J, O'Keefe B, Chikwamba R, Morris L.

Virology. 2010 Jun 20;402(1):187-96. doi: 10.1016/j.virol.2010.03.021. Epub 2010 Apr 13.

6.
7.

The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin.

Xue J, Gao Y, Hoorelbeke B, Kagiampakis I, Zhao B, Demeler B, Balzarini J, Liwang PJ.

Mol Pharm. 2012 Sep 4;9(9):2613-25. doi: 10.1021/mp300194b. Epub 2012 Aug 21.

8.

Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1.

Hoorelbeke B, Xue J, LiWang PJ, Balzarini J.

PLoS One. 2013 May 31;8(5):e64132. doi: 10.1371/journal.pone.0064132. Print 2013.

9.

The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism.

Xue J, Hoorelbeke B, Kagiampakis I, Demeler B, Balzarini J, Liwang PJ.

Antimicrob Agents Chemother. 2013 Aug;57(8):3976-89. doi: 10.1128/AAC.00332-13. Epub 2013 Jun 10.

10.

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

Richardson TM Jr, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW.

J Virol. 1996 Feb;70(2):753-62.

11.

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.

Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.

12.

Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains.

Luallen RJ, Agrawal-Gamse C, Fu H, Smith DF, Doms RW, Geng Y.

Glycobiology. 2010 Mar;20(3):280-6. doi: 10.1093/glycob/cwp184. Epub 2009 Nov 17.

13.

Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.

Mori T, O'Keefe BR, Sowder RC 2nd, Bringans S, Gardella R, Berg S, Cochran P, Turpin JA, Buckheit RW Jr, McMahon JB, Boyd MR.

J Biol Chem. 2005 Mar 11;280(10):9345-53. Epub 2004 Dec 21.

14.
15.

Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans.

Agrawal-Gamse C, Luallen RJ, Liu B, Fu H, Lee FH, Geng Y, Doms RW.

J Virol. 2011 Jan;85(1):470-80. doi: 10.1128/JVI.01349-10. Epub 2010 Oct 20.

16.

Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component.

O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, Mirsalis J, d'Andrea AL, Hume SD, Bratcher B, Saucedo CJ, McMahon JB, Pogue GP, Palmer KE.

Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6099-104. doi: 10.1073/pnas.0901506106. Epub 2009 Mar 30.

17.

IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP.

AIDS Res Hum Retroviruses. 2010 Apr;26(4):445-58. doi: 10.1089/aid.2009.0223.

18.

An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.

Luallen RJ, Lin J, Fu H, Cai KK, Agrawal C, Mboudjeka I, Lee FH, Montefiori D, Smith DF, Doms RW, Geng Y.

J Virol. 2008 Jul;82(13):6447-57. doi: 10.1128/JVI.00412-08. Epub 2008 Apr 23.

19.

Potent strategy to inhibit HIV-1 by binding both gp120 and gp41.

Kagiampakis I, Gharibi A, Mankowski MK, Snyder BA, Ptak RG, Alatas K, LiWang PJ.

Antimicrob Agents Chemother. 2011 Jan;55(1):264-75. doi: 10.1128/AAC.00376-10. Epub 2010 Oct 18.

20.

Preferential antibody recognition of structurally distinct HIV-1 gp120 molecules.

VanCott TC, Bethke FR, Kalyanaraman V, Burke DS, Redfield RR, Birx DL.

J Acquir Immune Defic Syndr. 1994 Nov;7(11):1103-15.

PMID:
7523653

Supplemental Content

Support Center